Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Sanofi, AstraZeneca in respiratory deal
by Rick Mullin
March 13, 2017
| A version of this story appeared in
Volume 95, Issue 11
Sanofi Pasteur and MedImmune, the biologics arm of AstraZeneca, have agreed to develop MED18897, a monoclonal antibody, for the prevention of lower respiratory tract illness caused by respiratory syncytial virus. MED18897 is currently in a Phase II clinical trial involving infants ineligible for Synagis, the current standard of care. Sanofi Pasteur will make an up-front payment of $127 million to MedImmune and milestone payments of up to $523 million.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X